financetom
Business
financetom
/
Business
/
JPMorgan CEO Dimon's 2024 compensation rises about 8%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan CEO Dimon's 2024 compensation rises about 8%
Jan 23, 2025 1:54 PM

Jan 23 (Reuters) - JPMorgan Chase ( JPM ) said on

Thursday CEO Jamie Dimon's 2024 compensation climbed about 8.3%

to $39 million.

The pay package included a base salary of $1.5 million and

$37.5 million in incentives.

The head of the largest U.S. lender was paid $36 million for

2023 after $34.5 million both in 2021 and 2022 against a

backdrop of economic uncertainty, geopolitical tensions and the

lingering effects of the COVID-19 pandemic.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mexico's Central Bank Opens Door to 50bps Rate Cut at Next Meeting After Thursday's 25bps Reduction, Notes BBVA Research
Mexico's Central Bank Opens Door to 50bps Rate Cut at Next Meeting After Thursday's 25bps Reduction, Notes BBVA Research
Dec 20, 2024
06:12 AM EST, 12/20/2024 (MT Newswires) -- The Board members of Mexico's central bank (Banxico) voted unanimously to cut the policy rate by 25 bps to 10.0% on Thursday, noted BBVA Research. The policy statement's forward guidance signals that a string of consecutive rate cuts is set to continue ahead and opens the door for considering larger cuts at some...
Humacyte Gets FDA's Full Approval for Universally Implantable Bioengineered Human Tissue; Shares Soar Premarket
Humacyte Gets FDA's Full Approval for Universally Implantable Bioengineered Human Tissue; Shares Soar Premarket
Dec 20, 2024
06:10 AM EST, 12/20/2024 (MT Newswires) -- Humacyte ( HUMA ) said late Thursday that the US Food and Drug Administration granted full approval for SYMVESS, a bioengineered human tissue designed to be universally implantable. Shares of the company rose more than 35% in recent premarket activity Friday. The approval is for SYMVESS' use in adults as a vascular conduit...
UK regulator says it could clear Synopsys' $35 bln Ansys acquisition if concerns are resolved
UK regulator says it could clear Synopsys' $35 bln Ansys acquisition if concerns are resolved
Dec 20, 2024
Dec 20 (Reuters) - UK's competition watchdog said on Friday it could approve chip design software maker Synopsys' ( SNPS ) $35 billion acquisition of Ansys ( ANSS ) if the regulator's concerns are resolved. ...
Turmoil at Colombia's Ecopetrol raises profit fears ahead of US investment decision
Turmoil at Colombia's Ecopetrol raises profit fears ahead of US investment decision
Dec 20, 2024
BARRANCABERMEJA, Colombia (Reuters) - Alleged interference by Colombian President Gustavo Petro in majority state-owned Ecopetrol and purges of hundreds of staff to make way for pro-government replacements are fueling fears about the energy company's future profits and contributions to the economy.  The worries, according to interviews with workers, ex-employees, a former board member and analysts, come ahead of a March...
Copyright 2023-2026 - www.financetom.com All Rights Reserved